ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.6 -0.01 (-0.63%)	---	---	---	-0.06 (-3.75%)	0.03 (1.92%)	0.0 (0.0%)	-0.06 (-3.71%)

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.37
Diluted EPS:: -0.37
Basic P/E:: -4.2973
Diluted P/E:: -4.2973
RSI(14) 1m:: 40.0
VWAP:: 1.59
RVol:: 1.3561

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	1.62 +0.02 (+1.25%)	Oct 15 10:31
1m	Price increase 1m	1.6 +0.02 (+1.27%)	Oct 15 10:19
1m	Price decrease 1m	1.58 -0.03 (-1.56%)	Oct 15 10:09
1m	Price increase 1m	1.59 +0.03 (+1.93%)	Oct 15 09:48
1m	Price increase 1m	1.58 +0.02 (+1.61%)	Oct 15 09:41